FTC Files Contempt Motion Against Amare Global and Three Individuals Over Unsubstantiated Health Claims
FTC targets deceptive health claims affecting aesthetic practices.
What changed & why it matters
MedSpaRadar recorded an FTC enforcement action at the federal level, dated June 12, 2026, in the Marketing & Advertising category.
An FTC action targets deceptive or unsubstantiated marketing. Aesthetic and weight-loss advertising — before/after claims, "clinically proven," GLP-1 results — is squarely in the FTC's lane, and an enforcement action sets the precedent a practice's own marketing is measured against.
- Type
- FTC Enforcement
- Jurisdiction
- Federal
- Category
- Marketing & Advertising
- Recorded
- June 12, 2026
What this means for your practice — the step to take, the deadline to calendar or the supplier detail to check, where the change calls for one — is in the member "what to do" below. This page is the free record of what changed and why it matters.
What to do
Free weekly Brief
Get the changes that matter in plain English, every week — and be alerted when the rules move. No charge.
Members get a specific “what to do” wherever a change calls for one — in one daily email, for your states. See one unlocked → · Pricing →
FTC Enforcement · primary source ↗
MedSpaRadar is regulatory monitoring and reference: it summarizes public laws, regulations and agency actions and links each to its source. It is not legal, medical, or compliance advice, and using it creates no attorney-client relationship. A summary can lag its source or leave out detail, and monitoring itself can be interrupted — so an absence of alerts means nothing reached you, not that nothing happened. Read the cited source, check its effective date, and confirm any change to your operations or clinical practice with qualified health-law counsel and your medical director.